10-29-2018 02:20 PM CET - Advertising, Media Consulting, Marketing Research
Print

Female Sexual Dysfunction Market Comprehensive Study by Leading Key Players- GlaxoSmithKline, Kuhnil Pharmaceutical, Met P Pharma AG

Press release from: HTF Market Intelligence Consulting Pvt. Ltd.
Female Sexual Dysfunction Market
Female Sexual Dysfunction Market
HTF Market Report released a new research document of 67 pages on industry titled as 'Female Sexual Dysfunction - Pipeline Review, H1 2018' with detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis that includes important players/vendors such as Callitas Therapeutics Inc, Dare Bioscience Inc, Emotional Brain BV, EndoCeutics Inc, Fabre-Kramer Pharmaceuticals Inc, GlaxoSmithKline Plc, Kuhnil Pharmaceutical Co Ltd, M et P Pharma AG, Palatin Technologies Inc, Pivot Pharmaceuticals Inc, Re-Pharm Ltd, S1 Biopharma IncThe report will help you gain market insights, future trends and growth prospects for forecast period of 2018 – 2022.

Request a sample report @ www.htfmarketreport.com/sample-report/1208911-female-sexu...

Summary

HTF MI latest Pharmaceutical and Healthcare disease pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2018, provides an overview of the Female Sexual Dysfunction (Women's Health) pipeline landscape.

Female sexual dysfunction occurs when a woman is not able to fully, healthily, and pleasurably experience some or all of the various physical stages the body normally experiences during sexual activity. The predisposing factors include depression or anxiety, heart and blood vessel disease, liver or kidney failure and certain medications, such as antidepressants or high blood pressure medications. Treatment includes estrogen therapy.

Report Highlights

HTF MI Pharmaceutical and Healthcare latest pipeline guide Female Sexual Dysfunction - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Female Sexual Dysfunction (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Female Sexual Dysfunction (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Female Sexual Dysfunction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 6, 1, 5, 2 and 1 respectively.

Female Sexual Dysfunction (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from HTF MI proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Get Customization in the Report, Enquire Now @ www.htfmarketreport.com/enquiry-before-buy/1208911-female...

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Female Sexual Dysfunction (Women's Health).
- The pipeline guide reviews pipeline therapeutics for Female Sexual Dysfunction (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Female Sexual Dysfunction (Women's Health) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Female Sexual Dysfunction (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Female Sexual Dysfunction (Women's Health)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Female Sexual Dysfunction (Women's Health).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Female Sexual Dysfunction (Women's Health) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned in the Report: Callitas Therapeutics Inc, Dare Bioscience Inc, Emotional Brain BV, EndoCeutics Inc, Fabre-Kramer Pharmaceuticals Inc, GlaxoSmithKline Plc, Kuhnil Pharmaceutical Co Ltd, M et P Pharma AG, Palatin Technologies Inc, Pivot Pharmaceuticals Inc, Re-Pharm Ltd, S1 Biopharma Inc

Buy this report @ www.htfmarketreport.com/buy-now?format=1&report=1208911

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Female Sexual Dysfunction - Overview
Female Sexual Dysfunction - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Female Sexual Dysfunction - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Female Sexual Dysfunction - Companies Involved in Therapeutics Development
Callitas Therapeutics Inc
Dare Bioscience Inc
Emotional Brain BV
EndoCeutics Inc
Fabre-Kramer Pharmaceuticals Inc
....Continued

View Detailed Table of Content @ www.htfmarketreport.com/reports/1208911-female-sexual-dys...

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

About Author:
HTF Market Report is a wholly owned brand of HTF market Intelligence Consulting Private Limited. HTF Market Report global research and market intelligence consulting organization is uniquely positioned to not only identify growth opportunities but to also empower and inspire you to create visionary growth strategies for futures, enabled by our extraordinary depth and breadth of thought leadership, research, tools, events and experience that assist you for making goals into a reality. Our understanding of the interplay between industry convergence, Mega Trends, technologies and market trends provides our clients with new business models and expansion opportunities. We are focused on identifying the “Accurate Forecast” in every industry we cover so our clients can reap the benefits of being early market entrants and can accomplish their “Goals & Objectives”.

Contact US :
Craig Francis (PR & Marketing Manager)
HTF Market Intelligence Consulting Private Limited
Unit No. 429, Parsonage Road Edison, NJ
New Jersey USA – 08837
Phone: +1 (206) 317 1218
sales@htfmarketreport.com

Connect with us at
www.linkedin.com/company/13388569/
www.facebook.com/htfmarketintelligence/
twitter.com/htfmarketreport
plus.google.com/u/0/+NidhiBhawsar-SEO_Expert?rel=author

This release was published on openPR.
News-ID: 1336273 • Views: 124
More releasesMore releases

You can edit or delete your press release here: